With the rapid social and economic development, frequent workplace and traffic accidents, and natural disasters such as earthquakes, the incidence of patients with traumatic spinal cord injury (SCI) is increasing year by year. Currently, there are 300,000-500,000 spinal cord injury patients in the United States, and the cost of treatment is as high as $25 billion/year. In China, there are about 1 million people with spinal cord injury, and the rate of 10,000 people per year is increasing, and the annual incidence of spinal cord injury in some areas is 60 people per million. Spinal cord injury (SCI) not only seriously impairs the patient’s somatic motor and sensory functions, but also causes the loss of regulation and innervation of the higher centers (brain and/or spinal cord) of the visceral organs below the plane of injury, resulting in neuropathic dysfunction (neuropathic dysfunction), and the pelvic floor organs innervated by the spinal cord (vesico-urethral, recto-anal and sexual) dysfunction is the most common. Supraconal SCI occurs above the spinal urinary center (S2-4 segment), and after recovery from spinal shock, it mostly develops into spastic bladder, and the patient’s bladder is doubly impaired in urinary storage and voiding. On the other hand, continuous bladder spasm causes intravesical hypertension, which causes retrograde renal impairment through ureteral reflux and even renal failure uremia, which is the most harmful to the survival life of patients and is the first cause of death of SCI patients in the late stage (referring to 1 year after SCI occurs). Neuroprosthesis is an electronic device that helps restore the function of nerve after injury, replacing nerve impulses sent by the brain with artificial electrical stimulation to control muscle activity, SARS) technique was applied to SCI patients in 1976, and good voiding results were obtained. The electrical stimulation device, called the Vocare Neuroprosthesis, was approved by the FDA in 1998 and has been used in more than 2,000 clinical cases worldwide until 2000. In order to expand the bladder capacity to obtain urinary storage, eradicate reflex incontinence and reduce the uncoordinated contraction of the sphincter, it is more effective to perform de-afferatation by sacral posterior root rhizotomy. At present, implantation of a voiding nerve prosthesis with complete sacral posterior root rhizotomy is considered to be the most ideal method to treat voiding dysfunction in SCI patients. After surgery, patients can actively control urination, increase bladder capacity and compliance, reduce residual urine volume, reduce the chance of urinary tract infection, assist defecation and penile erection, reduce constipation, and improve the quality of life and reduce mortality in paraplegic patients.